
Claims

~~[Claim 1]~~

1. ~~A pharmaceutical composition, wherein~~ ~~an~~ Use of an antibody-drug conjugate in the manufacture of a medicament for treating cancer, wherein the antibody-drug conjugate is to be administered in combination with ~~and~~ an anti-SIRPα antibody ~~are administered in combination~~, ~~and~~wherein

the antibody-drug conjugate is an antibody-drug conjugate in which a drug-linker represented by the following formula is conjugated to an antibody via a thioether bond:

~~[Formula 1]~~



wherein A represents the connecting position to ~~an~~ the antibody~~,~~

~~is conjugated to the antibody via a thioether bond~~.

~~[Claim 2]~~

2. The usepharmaceutical composition according to claim 1, wherein the antibody in the antibody-drug conjugate is an anti-HER2 antibody, an anti-HER3 antibody, an anti-TROP2 antibody, an anti-B7-H3 antibody, an anti-GPR20 antibody, or an anti-CDH6 antibody.

[Claim 3]

3. The use pharmaceutical composition according to claim 2, wherein the antibody in the antibody-drug conjugate is an anti-HER2 antibody.

[Claim 4]

4. The use pharmaceutical composition according to claim 3, wherein the anti-HER2 antibody is an antibody comprising a heavy chain consisting of an amino acid sequence consisting of amino acid residues 1 to 449 of SEQ ID NO: 1 and a light chain consisting of an amino acid sequence consisting of amino acid residues 1 to 214 of SEQ ID NO: 2.

[Claim 5]

5. The use pharmaceutical composition according to claim 3, wherein the anti-HER2 antibody is an antibody comprising a heavy chain consisting of an amino acid sequence represented by SEQ ID NO: 1 and a light chain consisting of an amino acid sequence represented by SEQ ID NO: 2.

[Claim 6]

6. The use pharmaceutical composition according to any one of claims 3 to 5, wherein the average number of units

of the drug-linker conjugated per antibody molecule in the antibody-drug conjugate is in the range of from 7 to 8.

~~[Claim 7]~~

7. The use ~~pharmaceutical composition~~ according to claim 2, wherein the antibody in the antibody-drug conjugate is an anti-HER3 antibody.

~~[Claim 8]~~

8. The use ~~pharmaceutical composition~~ according to claim 7, wherein the anti-HER3 antibody is an antibody comprising a heavy chain consisting of an amino acid sequence represented by SEQ ID NO: 3 and a light chain consisting of an amino acid sequence represented by SEQ ID NO: 4.

~~[Claim 9]~~

9. The use ~~pharmaceutical composition~~ according to claim ~~8~~7, wherein the anti-HER3 antibody ~~lacks a lysine residue at the carboxyl terminus of the heavy chain~~is an antibody comprising a heavy chain consisting of an amino acid sequence consisting of amino acid residues 1 to 446 of SEQ ID NO: 3 and a light chain consisting of an amino acid sequence represented by SEQ ID NO: 4.

~~[Claim 10]~~

10. The use ~~pharmaceutical composition~~ according to any one of claims 7 to 9, wherein the average number of units of the drug-linker conjugated per antibody molecule in

the antibody-drug conjugate is in the range of from 7 to 8.

~~[Claim 11]~~

11. The use ~~pharmaceutical composition~~ according to claim 2, wherein the antibody in the antibody-drug conjugate is an anti-TROP2 antibody.

~~[Claim 12]~~

12. The use ~~pharmaceutical composition~~ according to claim 11, wherein the anti-TROP2 antibody is an antibody comprising a heavy chain consisting of an amino acid sequence consisting of amino acid residues 20 to 470 of SEQ ID NO: 5 and a light chain consisting of an amino acid sequence consisting of amino acid residues 21 to 234 of SEQ ID NO: 6.

~~[Claim 13]~~

13. The use ~~pharmaceutical composition~~ according to claim ~~12~~11, wherein the anti-TROP2 antibody ~~lacks a lysine residue at the carboxyl terminus of the heavy chain~~is an antibody comprising a heavy chain consisting of an amino acid sequence consisting of amino acid residues 20 to 469 of SEQ ID NO: 5 and a light chain consisting of an amino acid sequence consisting of amino acid residues 21 to 234 of SEQ ID NO: 6.

~~[Claim 14]~~

14. The use ~~pharmaceutical composition~~ according to any one of claims 11 to 13, wherein the average number of units of the drug-linker conjugated per antibody molecule

in the antibody-drug conjugate is in the range of from 3.5 to 4.5.

~~[Claim 15]~~

15. The use ~~pharmaceutical composition~~ according to claim 2, wherein the antibody in the antibody-drug conjugate is an anti-B7-H3 antibody.

~~[Claim 16]~~

16. The use ~~pharmaceutical composition~~ according to claim 15, wherein the anti-B7-H3 antibody is an antibody comprising a heavy chain consisting of an amino acid sequence consisting of amino acid residues 20 to 471 of SEQ ID NO: 7 and a light chain consisting of an amino acid sequence consisting of amino acid residues 21 to 233 of SEQ ID NO: 8.

~~[Claim 17]~~

17. The use ~~pharmaceutical composition~~ according to claim ~~16~~15, wherein the anti-B7-H3 antibody ~~lacks a lysine residue at the carboxyl terminus of the heavy chain~~is an antibody comprising a heavy chain consisting of an amino acid sequence consisting of amino acid residues 20 to 470 of SEQ ID NO: 7 and a light chain consisting of an amino acid sequence consisting of amino acid residues 21 to 233 of SEQ ID NO: 8.

~~[Claim 18]~~

18. The use ~~pharmaceutical composition~~ according to any one of claims 15 to 17, wherein the average number of units of the drug-linker conjugated per antibody molecule

in the antibody-drug conjugate is in the range of from 3.5 to 4.5.

~~[Claim 19]~~

19. The use ~~pharmaceutical composition~~ according to claim 2, wherein the antibody in the antibody-drug conjugate is an anti-GPR20 antibody.

~~[Claim 20]~~

20. The use ~~pharmaceutical composition~~ according to claim 19, wherein the anti-GPR20 antibody is an antibody comprising a heavy chain consisting of an amino acid sequence consisting of amino acid residues 20 to 472 of SEQ ID NO: 9 and a light chain consisting of an amino acid sequence consisting of amino acid residues 21 to 234 of SEQ ID NO: 10.

~~[Claim 21]~~

21. The use ~~pharmaceutical composition~~ according to claim ~~20~~19, wherein the anti-GPR20 antibody ~~lacks a lysine residue at the carboxyl terminus of the heavy chain~~is an antibody comprising a heavy chain consisting of an amino acid sequence consisting of amino acid residues 20 to 471 of SEQ ID NO: 9 and a light chain consisting of an amino acid sequence consisting of amino acid residues 21 to 234 of SEQ ID NO: 10.

~~[Claim 22]~~

22. The use ~~pharmaceutical composition~~ according to any one of claims 19 to 21, wherein the average number of units of the drug-linker conjugated per antibody molecule

in the antibody-drug conjugate is in the range of from 7 to 8.

~~[Claim 23]~~

23. The use ~~pharmaceutical composition~~ according to claim 2, wherein the antibody in the antibody-drug conjugate is an anti-CDH6 antibody.

~~[Claim 24]~~

24. The use ~~pharmaceutical composition~~ according to claim 23, wherein the anti-CDH6 antibody is an antibody comprising a heavy chain consisting of an amino acid sequence consisting of amino acid residues 20 to 471 of SEQ ID NO: 11 and a light chain consisting of an amino acid sequence consisting of amino acid residues 21 to 233 of SEQ ID NO: 12.

~~[Claim 25]~~

25. The use ~~pharmaceutical composition~~ according to claim ~~24~~23, wherein the anti-CDH6 antibody ~~lacks a lysine residue at the carboxyl terminus of the heavy chain~~is an antibody comprising a heavy chain consisting of an amino acid sequence consisting of amino acid residues 20 to 470 of SEQ ID NO: 11 and a light chain consisting of an amino acid sequence consisting of amino acid residues 21 to 233 of SEQ ID NO: 12.

~~[Claim 26]~~

26. The use ~~pharmaceutical composition~~ according to any one of claims 23 to 25, wherein the average number of units of the drug-linker conjugated per antibody molecule

in the antibody-drug conjugate is in the range of from 7 to 8.

~~[Claim 27]~~

27. The use ~~pharmaceutical composition~~ according to any one of claims 1 to 26, wherein the anti-SIRPα antibody is any one of the following antibodies (1) to (5):

(1) an antibody comprising a heavy chain consisting of an amino acid sequence consisting of amino acid residues 20 to 466 of SEQ ID NO: 13 and a light chain consisting of an amino acid sequence consisting of amino acid residues 21 to 234 of SEQ ID NO: 16;

(2) an antibody comprising a heavy chain consisting of an amino acid sequence consisting of amino acid residues 20 to 466 of SEQ ID NO: 13 and a light chain consisting of an amino acid sequence consisting of amino acid residues 21 to 234 of SEQ ID NO: 17;

(3) an antibody comprising a heavy chain consisting of an amino acid sequence consisting of amino acid residues 20 to 466 of SEQ ID NO: 14 and a light chain consisting of an amino acid sequence consisting of amino acid residues 21 to 234 of SEQ ID NO: 15;

(4) an antibody comprising a heavy chain consisting of an amino acid sequence consisting of amino acid residues 20 to 466 of SEQ ID NO: 14 and a light chain consisting of an amino acid sequence consisting of amino acid residues 21 to 234 of SEQ ID NO: 16; and

(5) an antibody according to any one of (1) to (4), lacking a lysine residue at the carboxyl terminus of the heavy chain.

~~[Claim 28]~~

28. The use ~~pharmaceutical composition~~ according to any one of claims 1 to 27, wherein the antibody-drug conjugate and the anti-SIRPα antibody are separately contained as active components in different formulations, and are to be administered simultaneously or at different times.

~~[Claim 29]~~


29. The use ~~pharmaceutical composition~~ according to any one of claims 1 to 28, wherein the ~~composition is for treating~~cancer is at least one selected from the group consisting of breast cancer, gastric cancer, colorectal cancer, lung cancer, esophageal cancer, salivary gland cancer, gastroesophageal junction adenocarcinoma, biliary tract cancer, Paget's disease, pancreatic cancer, ovarian cancer, bladder cancer, prostate cancer, uterine cancer, sarcoma, head and neck cancer, hepatocellular cancer, cervical cancer, brain tumor, glioma, eye tumor, thyroid cancer, thymus cancer, gallbladder cancer, lymphoma, leukemia, and myelodysplastic syndrome.

~~[Claim 30]~~

~~A pharmaceutical composition, wherein an antibody-drug conjugate and an anti-SIRPα antibody are administered in combination, and~~

~~the antibody-drug conjugate is an antibody-drug conjugate represented by the following formula:~~

~~[Formula 2]~~



~~wherein a drug-linker is conjugated to an antibody via a thioether bond; and n represents the average number of units of the drug-linker conjugated per antibody molecule.~~

~~[Claim 31]~~

~~The pharmaceutical composition according to claim 30, wherein the antibody in the antibody-drug conjugate is an anti-HER2 antibody, an anti-HER3 antibody, an anti-TROP2 antibody, an anti-B7-H3 antibody, an anti-GPR20 antibody, or an anti-CDH6 antibody.~~

~~[Claim 32]~~

~~The pharmaceutical composition according to claim 31, wherein the antibody in the antibody-drug conjugate is an anti-HER2 antibody.~~

~~[Claim 33]~~

~~The pharmaceutical composition according to claim 32, wherein the anti-HER2 antibody is an antibody~~

~~comprising a heavy chain consisting of an amino acid sequence consisting of amino acid residues 1 to 449 of SEQ ID NO: 1 and a light chain consisting of an amino acid sequence consisting of amino acid residues 1 to 214 of SEQ ID NO: 2.~~

~~[Claim 34]~~

~~The pharmaceutical composition according to claim 32, wherein the anti-HER2 antibody is an antibody comprising a heavy chain consisting of an amino acid sequence represented by SEQ ID NO: 1 and a light chain consisting of an amino acid sequence represented by SEQ ID NO: 2.~~

~~[Claim 35]~~

~~The pharmaceutical composition according to any one of claims 32 to 34, wherein the average number of units of the drug-linker conjugated per antibody molecule in the antibody-drug conjugate is in the range of from 7 to 8.~~

~~[Claim 36]~~

~~The pharmaceutical composition according to claim 31, wherein the antibody in the antibody-drug conjugate is an anti-HER3 antibody.~~

~~[Claim 37]~~

~~The pharmaceutical composition according to claim 36, wherein the anti-HER3 antibody is an antibody comprising a heavy chain consisting of an amino acid sequence represented by SEQ ID NO: 3 and a light chain~~

~~consisting of an amino acid sequence represented by SEQ ID NO: 4.~~

~~[Claim 38]~~

~~The pharmaceutical composition according to claim 37, wherein the anti-HER3 antibody lacks a lysine residue at the carboxyl terminus of the heavy chain.~~

~~[Claim 39]~~

~~The pharmaceutical composition according to any one of claims 36 to 38, wherein the average number of units of the drug-linker conjugated per antibody molecule in the antibody-drug conjugate is in the range of from 7 to 8.~~

~~[Claim 40]~~

~~The pharmaceutical composition according to claim 31, wherein the antibody in the antibody-drug conjugate is an anti-TROP2 antibody.~~

~~[Claim 41]~~

~~The pharmaceutical composition according to claim 40, wherein the anti-TROP2 antibody is an antibody comprising a heavy chain consisting of an amino acid sequence consisting of amino acid residues 20 to 470 of SEQ ID NO: 5 and a light chain consisting of an amino acid sequence consisting of amino acid residues 21 to 234 of SEQ ID NO: 6.~~

~~[Claim 42]~~

~~The pharmaceutical composition according to claim 41, wherein the anti-TROP2 antibody lacks a lysine residue at the carboxyl terminus of the heavy chain.~~

~~[Claim 43]~~

~~The pharmaceutical composition according to any one of claims 40 to 42, wherein the average number of units of the drug-linker conjugated per antibody molecule in the antibody-drug conjugate is in the range of from 3.5 to 4.5.~~

~~[Claim 44]~~

~~The pharmaceutical composition according to claim 31, wherein the antibody in the antibody-drug conjugate is an anti-B7-H3 antibody.~~

~~[Claim 45]~~

~~The pharmaceutical composition according to claim 44, wherein the anti-B7-H3 antibody is an antibody comprising a heavy chain consisting of an amino acid sequence consisting of amino acid residues 20 to 471 of SEQ ID NO: 7 and a light chain consisting of an amino acid sequence consisting of amino acid residues 21 to 233 of SEQ ID NO: 8.~~

~~[Claim 46]~~

~~The pharmaceutical composition according to claim 45, wherein the anti-B7-H3 antibody lacks a lysine residue at the carboxyl terminus of the heavy chain.~~

~~[Claim 47]~~

~~The pharmaceutical composition according to any one of claims 44 to 46, wherein the average number of units of the drug-linker conjugated per antibody molecule in the antibody-drug conjugate is in the range of from 3.5 to 4.5~~

~~[Claim 48]~~

~~The pharmaceutical composition according to claim 31, wherein the antibody in the antibody-drug conjugate is an anti-GPR20 antibody~~

~~[Claim 49]~~

~~The pharmaceutical composition according to claim 48, wherein the anti-GPR20 antibody is an antibody comprising a heavy chain consisting of an amino acid sequence consisting of amino acid residues 20 to 472 of SEQ ID NO: 9 and a light chain consisting of an amino acid sequence consisting of amino acid residues 21 to 234 of SEQ ID NO: 10.~~

~~[Claim 50]~~

~~The pharmaceutical composition according to claim 49, wherein the anti-GPR20 antibody lacks a lysine residue at the carboxyl terminus of the heavy chain.~~

~~[Claim 51]~~

~~The pharmaceutical composition according to any one of claims 48 to 50, wherein the average number of units of the drug-linker conjugated per antibody molecule in the antibody-drug conjugate is in the range of from 7 to 8.~~

~~[Claim 52]~~

~~The pharmaceutical composition according to claim 31, wherein the antibody in the antibody-drug conjugate is an anti-CDH6 antibody.~~

~~[Claim 53]~~

~~The pharmaceutical composition according to claim 52, wherein the anti-CDH6 antibody is an antibody comprising a heavy chain consisting of an amino acid sequence consisting of amino acid residues 20 to 471 of SEQ ID NO: 11 and a light chain consisting of an amino acid sequence consisting of amino acid residues 21 to 233 of SEQ ID NO: 12.~~

~~[Claim 54]~~

~~The pharmaceutical composition according to claim 53, wherein the anti-CDH6 antibody lacks a lysine residue at the carboxyl terminus of the heavy chain.~~

~~[Claim 55]~~

~~The pharmaceutical composition according to any one of claims 52 to 54, wherein the average number of units of the drug-linker conjugated per antibody molecule in the antibody-drug conjugate is in the range of from 7 to 8.~~

~~[Claim 56]~~

~~The pharmaceutical composition according to any one of claims 30 to 55, wherein the anti-SIRPα antibody is any one of the following antibodies (1) to (5):~~

~~(1) an antibody comprising a heavy chain consisting of an amino acid sequence consisting of amino acid residues 20 to 466 of SEQ ID NO: 13 and a light chain consisting of an amino acid sequence consisting of amino acid residues 21 to 234 of SEQ ID NO: 16;~~

~~(2) an antibody comprising a heavy chain consisting of an amino acid sequence consisting of amino acid residues 20 to 466 of SEQ ID NO: 13 and a light chain consisting of an amino acid sequence consisting of amino acid residues 21 to 234 of SEQ ID NO: 17;~~

~~(3) an antibody comprising a heavy chain consisting of an amino acid sequence consisting of amino acid residues 20 to 466 of SEQ ID NO: 14 and a light chain consisting of an amino acid sequence consisting of amino acid residues 21 to 234 of SEQ ID NO: 15;~~

~~(4) an antibody comprising a heavy chain consisting of an amino acid sequence consisting of amino acid residues 20 to 466 of SEQ ID NO: 14 and a light chain consisting of an amino acid sequence consisting of amino acid residues 21 to 234 of SEQ ID NO: 16; and~~

~~(5) an antibody according to any one of (1) to (4), lacking a lysine residue at the carboxyl terminus of the heavy chain.~~

~~[Claim 57]~~

~~The pharmaceutical composition according to any one of claims 30 to 56, wherein the antibody-drug conjugate and the anti-SIRPα antibody are separately contained as~~

~~active components in different formulations, and are administered simultaneously or at different times.~~

~~[Claim 58]~~


~~The pharmaceutical composition according to any one of claims 30 to 57, wherein the composition is for treating at least one selected from the group consisting of breast cancer, gastric cancer, colorectal cancer, lung cancer, esophageal cancer, salivary gland cancer, gastroesophageal junction adenocarcinoma, biliary tract cancer, Paget's disease, pancreatic cancer, ovarian cancer, bladder cancer, prostate cancer, uterine cancer, sarcoma, head and neck cancer, hepatocellular cancer, cervical cancer, brain tumor, glioma, eye tumor, thyroid cancer, thymus cancer, gallbladder cancer, lymphoma, leukemia, and myelodysplastic syndrome.~~

~~[Claim 59]~~

30. A ~~method of treatment,~~pharmaceutical composition comprising ~~administering~~ an antibody-drug conjugate and an anti-SIRPα antibody~~ in combination to a subject in need of treatment~~, wherein

the antibody-drug conjugate and the anti-SIRPα antibody are as defined in any one of claims 1 to 27~~is an antibody-drug conjugate in which a drug-linker represented by the following formula:~~

~~[Formula 3]~~



~~wherein A represents the connecting position to an antibody,~~

~~is conjugated to the antibody via a thioether bond~~.

~~[Claim 60]~~

31. ~~The method of treatment according to claim 59, wherein the~~A kit of parts comprising:

(A) an ~~antibody in the~~ antibody-drug conjugate ~~is an anti-HER2 antibody, an anti-HER3 antibody, an anti-TROP2 antibody, an anti-B7-H3 antibody, an anti-GPR20 antibody, or an anti-CDH6 antibody~~as defined in any one of claims 2 to 26~~.~~; and

(B)

~~[Claim 61]~~

~~The method of treatment according to claim 60, wherein the antibody in the antibody-drug conjugate is an anti-HER2 antibody.~~

~~[Claim 62]~~

~~The method of treatment according to claim 61, wherein the anti-HER2 antibody is an antibody comprising~~

~~a heavy chain consisting of an amino acid sequence consisting of amino acid residues 1 to 449 of SEQ ID NO: 1 and a light chain consisting of an amino acid sequence consisting of amino acid residues 1 to 214 of SEQ ID NO: 2.~~

~~[Claim 63]~~

~~The method of treatment according to claim 61, wherein the anti-HER2 antibody is an antibody comprising a heavy chain consisting of an amino acid sequence represented by SEQ ID NO: 1 and a light chain consisting of an amino acid sequence represented by SEQ ID NO: 2.~~

~~[Claim 64]~~

~~The method of treatment according to any one of claims 61 to 63, wherein the average number of units of the drug-linker conjugated per antibody molecule in the antibody-drug conjugate is in the range of from 7 to 8.~~

~~[Claim 65]~~

~~The method of treatment according to claim 60, wherein the antibody in the antibody-drug conjugate is an anti-HER3 antibody.~~

~~[Claim 66]~~

~~The method of treatment according to claim 65, wherein the anti-HER3 antibody is an antibody comprising a heavy chain consisting of an amino acid sequence represented by SEQ ID NO: 3 and a light chain consisting of an amino acid sequence represented by SEQ ID NO: 4.~~

~~[Claim 67]~~

~~The method of treatment according to claim 66, wherein the anti-HER3 antibody lacks a lysine residue at the carboxyl terminus of the heavy chain.~~

~~[Claim 68]~~

~~The method of treatment according to any one of claims 65 to 67, wherein the average number of units of the drug-linker conjugated per antibody molecule in the antibody-drug conjugate is in the range of from 7 to 8.~~

~~[Claim 69]~~

~~The method of treatment according to claim 60, wherein the antibody in the antibody-drug conjugate is an anti-TROP2 antibody.~~

~~[Claim 70]~~

~~The method of treatment according to claim 69, wherein the anti-TROP2 antibody is an antibody comprising a heavy chain consisting of an amino acid sequence consisting of amino acid residues 20 to 470 of SEQ ID NO: 5 and a light chain consisting of an amino acid sequence consisting of amino acid residues 21 to 234 of SEQ ID NO: 6.~~

~~[Claim 71]~~

~~The method of treatment according to claim 70, wherein the anti-TROP2 antibody lacks a lysine residue at the carboxyl terminus of the heavy chain.~~

~~[Claim 72]~~

~~The method of treatment according to any one of claims 69 to 71, wherein the average number of units of~~

~~the drug-linker conjugated per antibody molecule in the antibody-drug conjugate is in the range of from 3.5 to 4.5.~~

~~[Claim 73]~~

~~The method of treatment according to claim 60, wherein the antibody in the antibody-drug conjugate is an anti-B7-H3 antibody.~~

~~[Claim 74]~~

~~The method of treatment according to claim 73, wherein the anti-B7-H3 antibody is an antibody comprising a heavy chain consisting of an amino acid sequence consisting of amino acid residues 20 to 471 of SEQ ID NO: 7 and a light chain consisting of an amino acid sequence consisting of amino acid residues 21 to 233 of SEQ ID NO: 8.~~

~~[Claim 75]~~

~~The method of treatment according to claim 74, wherein the anti-B7-H3 antibody lacks a lysine residue at the carboxyl terminus of the heavy chain.~~

~~[Claim 76]~~

~~The method of treatment according to any one of claims 73 to 75, wherein the average number of units of the drug-linker conjugated per antibody molecule in the antibody-drug conjugate is in the range of from 3.5 to 4.5.~~

~~[Claim 77]~~

~~The method of treatment according to claim 60, wherein the antibody in the antibody-drug conjugate is an anti-GPR20 antibody.~~

~~[Claim 78]~~

~~The method of treatment according to claim 77, wherein the anti-GPR20 antibody is an antibody comprising a heavy chain consisting of an amino acid sequence consisting of amino acid residues 20 to 472 of SEQ ID NO: 9 and a light chain consisting of an amino acid sequence consisting of amino acid residues 21 to 234 of SEQ ID NO: 10.~~

~~[Claim 79]~~

~~The method of treatment according to claim 78, wherein the anti-GPR20 antibody lacks a lysine residue at the carboxyl terminus of the heavy chain.~~

~~[Claim 80]~~

~~The method of treatment according to any one of claims 77 to 79, wherein the average number of units of the drug-linker conjugated per antibody molecule in the antibody-drug conjugate is in the range of from 7 to 8.~~

~~[Claim 81]~~

~~The method of treatment according to claim 60, wherein the antibody in the antibody-drug conjugate is an anti-CDH6 antibody.~~

~~[Claim 82]~~

~~The method of treatment according to claim 81, wherein the anti-CDH6 antibody is an antibody comprising~~

~~a heavy chain consisting of an amino acid sequence consisting of amino acid residues 20 to 471 of SEQ ID NO: 11 and a light chain consisting of an amino acid sequence consisting of amino acid residues 21 to 233 of SEQ ID NO: 12.~~

~~[Claim 83]~~

~~The method of treatment according to claim 82, wherein the anti-CDH6 antibody lacks a lysine residue at the carboxyl terminus of the heavy chain.~~

~~[Claim 84]~~

~~The method of treatment according to any one of claims 81 to 83, wherein the average number of units of the drug-linker conjugated per antibody molecule in the antibody-drug conjugate is in the range of from 7 to 8.~~

~~[Claim 85]~~

~~The method of treatment according to any one of claims 59 to 84, wherein the~~ an anti-SIRPα antibody ~~is any one of the following antibodies (1) to (5):~~

~~(1) an antibody comprising a heavy chain consisting of an amino acid sequence consisting of amino acid residues 20 to 466 of SEQ ID NO: 13 and a light chain consisting of an amino acid sequence consisting of amino acid residues 21 to 234 of SEQ ID NO: 16;~~

~~(2) an antibody comprising a heavy chain consisting of an amino acid sequence consisting of amino acid residues 20 to 466 of SEQ ID NO: 13 and a light chain~~

~~consisting of an amino acid sequence consisting of amino acid residues 21 to 234 of SEQ ID NO: 17;~~

~~(3) an antibody comprising a heavy chain consisting of an amino acid sequence consisting of amino acid residues 20 to 466 of SEQ ID NO: 14 and a light chain consisting of an amino acid sequence consisting of amino acid residues 21 to 234 of SEQ ID NO: 15;~~

~~(4) an antibody comprising a heavy chain consisting of an amino acid sequence consisting of amino acid residues 20 to 466 of SEQ ID NO: 14 and a light chain consisting of an amino acid sequence consisting of amino acid residues 21 to 234 of SEQ ID NO: 16; and~~

~~(5) an antibody according to any one of (1) to (4), lacking a lysine residue at the carboxyl terminus of the heavy chain~~as defined in claim 27.

~~[Claim 86]~~

~~The method of treatment according to any one of claims 59 to 85, wherein the antibody-drug conjugate and the anti-SIRPα antibody are separately contained as active components in different formulations, and are administered simultaneously or at different times.~~

~~[Claim 87]~~


~~The method of treatment according to any one of claims 59 to 86, wherein the method is for treating at least one selected from the group consisting of breast cancer, gastric cancer, colorectal cancer, lung cancer, esophageal cancer, salivary gland cancer,~~

~~gastroesophageal junction adenocarcinoma, biliary tract cancer, Paget's disease, pancreatic cancer, ovarian cancer, bladder cancer, prostate cancer, uterine cancer, sarcoma, head and neck cancer, hepatocellular cancer, cervical cancer, brain tumor, glioma, eye tumor, thyroid cancer, thymus cancer, gallbladder cancer, lymphoma, leukemia, and myelodysplastic syndrome.~~

~~[Claim 88]~~

~~A method of treatment, comprising administering an antibody-drug conjugate and an anti-SIRPα antibody in combination to a subject in need of treatment, wherein the antibody-drug conjugate is an antibody-drug conjugate represented by the following formula:~~

~~[Formula 4]~~



~~wherein a drug-linker is conjugated to an antibody via a thioether bond; and n represents the average number of units of the drug-linker conjugated per antibody molecule.~~

~~[Claim 89]~~

~~The method of treatment according to claim 88, wherein the antibody in the antibody-drug conjugate is an anti-HER2 antibody, an anti-HER3 antibody, an anti-TROP2 antibody, an anti-B7-H3 antibody, an anti-GPR20 antibody, or an anti-CDH6 antibody.~~

~~[Claim 90]~~

~~The method of treatment according to claim 89, wherein the antibody in the antibody-drug conjugate is an anti-HER2 antibody.~~

~~[Claim 91]~~

~~The method of treatment according to claim 90, wherein the anti-HER2 antibody is an antibody comprising a heavy chain consisting of an amino acid sequence consisting of amino acid residues 1 to 449 of SEQ ID NO: 1 and a light chain consisting of an amino acid sequence consisting of amino acid residues 1 to 214 of SEQ ID NO: 2.~~

~~[Claim 92]~~

~~The method of treatment according to claim 90, wherein the anti-HER2 antibody is an antibody comprising a heavy chain consisting of an amino acid sequence represented by SEQ ID NO: 1 and a light chain consisting of an amino acid sequence represented by SEQ ID NO: 2.~~

~~[Claim 93]~~

~~The method of treatment according to any one of claims 90 to 92, wherein the average number of units of~~

~~the drug-linker conjugated per antibody molecule in the antibody-drug conjugate is in the range of from 7 to 8.~~

~~[Claim 94]~~

~~The method of treatment according to claim 89, wherein the antibody in the antibody-drug conjugate is an anti-HER3 antibody.~~

~~[Claim 95]~~

~~The method of treatment according to claim 94, wherein the anti-HER3 antibody is an antibody comprising a heavy chain consisting of an amino acid sequence represented by SEQ ID NO: 3 and a light chain consisting of an amino acid sequence represented by SEQ ID NO: 4.~~

~~[Claim 96]~~

~~The method of treatment according to claim 95, wherein the anti-HER3 antibody lacks a lysine residue at the carboxyl terminus of the heavy chain.~~

~~[Claim 97]~~

~~The method of treatment according to any one of claims 94 to 96, wherein the average number of units of the drug-linker conjugated per antibody molecule in the antibody-drug conjugate is in the range of from 7 to 8.~~

~~[Claim 98]~~

~~The method of treatment according to claim 89, wherein the antibody in the antibody-drug conjugate is an anti-TROP2 antibody.~~

~~[Claim 99]~~

~~The method of treatment according to claim 98, wherein the anti-TROP2 antibody is an antibody comprising a heavy chain consisting of an amino acid sequence consisting of amino acid residues 20 to 470 of SEQ ID NO: 5 and a light chain consisting of an amino acid sequence consisting of amino acid residues 21 to 234 of SEQ ID NO: 6.~~

~~[Claim 100]~~

~~The method of treatment according to claim 99, wherein the anti-TROP2 antibody lacks a lysine residue at the carboxyl terminus of the heavy chain.~~

~~[Claim 101]~~

~~The method of treatment according to any one of claims 98 to 100, wherein the average number of units of the drug-linker conjugated per antibody molecule in the antibody-drug conjugate is in the range of from 3.5 to 4.5.~~

~~[Claim 102]~~

~~The method of treatment according to claim 89, wherein the antibody in the antibody-drug conjugate is an anti-B7-H3 antibody.~~

~~[Claim 103]~~

~~The method of treatment according to claim 102, wherein the anti-B7-H3 antibody is an antibody comprising a heavy chain consisting of an amino acid sequence consisting of amino acid residues 20 to 471 of SEQ ID NO: 7 and a light chain consisting of an amino acid sequence~~

~~consisting of amino acid residues 21 to 233 of SEQ ID NO: 8.~~

~~[Claim 104]~~

~~The method of treatment according to claim 103, wherein the anti-B7-H3 antibody lacks a lysine residue at the carboxyl terminus of the heavy chain.~~

~~[Claim 105]~~

~~The method of treatment according to any one of claims 102 to 104, wherein the average number of units of the drug-linker conjugated per antibody molecule in the antibody-drug conjugate is in the range of from 3.5 to 4.5.~~

~~[Claim 106]~~

~~The method of treatment according to claim 89, wherein the antibody in the antibody-drug conjugate is an anti-GPR20 antibody.~~

~~[Claim 107]~~

~~The method of treatment according to claim 106, wherein the anti-GPR20 antibody is an antibody comprising a heavy chain consisting of an amino acid sequence consisting of amino acid residues 20 to 472 of SEQ ID NO: 9 and a light chain consisting of an amino acid sequence consisting of amino acid residues 21 to 234 of SEQ ID NO: 10.~~

~~[Claim 108]~~

~~The method of treatment according to claim 107, wherein the anti-GPR20 antibody lacks a lysine residue at the carboxyl terminus of the heavy chain.~~

~~[Claim 109]~~

~~The method of treatment according to any one of claims 106 to 108, wherein the average number of units of the drug-linker conjugated per antibody molecule in the antibody-drug conjugate is in the range of from 7 to 8.~~

~~[Claim 110]~~

~~The method of treatment according to claim 89, wherein the antibody in the antibody-drug conjugate is an anti-CDH6 antibody.~~

~~[Claim 111]~~

~~The method of treatment according to claim 110, wherein the anti-CDH6 antibody is an antibody comprising a heavy chain consisting of an amino acid sequence consisting of amino acid residues 20 to 471 of SEQ ID NO: 11 and a light chain consisting of an amino acid sequence consisting of amino acid residues 21 to 233 of SEQ ID NO: 12.~~

~~[Claim 112]~~

~~The method of treatment according to claim 111, wherein the anti-CDH6 antibody lacks a lysine residue at the carboxyl terminus of the heavy chain.~~

~~[Claim 113]~~

~~The method of treatment according to any one of claims 110 to 112, wherein the average number of units of~~

~~the drug-linker conjugated per antibody molecule in the antibody-drug conjugate is in the range of from 7 to 8. [Claim 114]~~

~~The method of treatment according to any one of claims 88 to 113, wherein the anti-SIRPα antibody is any one of the following antibodies (1) to (5):~~

~~(1) an antibody comprising a heavy chain consisting of an amino acid sequence consisting of amino acid residues 20 to 466 of SEQ ID NO: 13 and a light chain consisting of an amino acid sequence consisting of amino acid residues 21 to 234 of SEQ ID NO: 16;~~

~~(2) an antibody comprising a heavy chain consisting of an amino acid sequence consisting of amino acid residues 20 to 466 of SEQ ID NO: 13 and a light chain consisting of an amino acid sequence consisting of amino acid residues 21 to 234 of SEQ ID NO: 17;~~

~~(3) an antibody comprising a heavy chain consisting of an amino acid sequence consisting of amino acid residues 20 to 466 of SEQ ID NO: 14 and a light chain consisting of an amino acid sequence consisting of amino acid residues 21 to 234 of SEQ ID NO: 15;~~

~~(4) an antibody comprising a heavy chain consisting of an amino acid sequence consisting of amino acid residues 20 to 466 of SEQ ID NO: 14 and a light chain consisting of an amino acid sequence consisting of amino acid residues 21 to 234 of SEQ ID NO: 16; and~~

~~(5) an antibody according to any one of (1) to (4), lacking a lysine residue at the carboxyl terminus of the heavy chain.~~

~~[Claim 115]~~

~~The method of treatment according to any one of claims 88 to 114, wherein the antibody-drug conjugate and the anti-SIRPα antibody are separately contained as active components in different formulations, and are administered simultaneously or at different times.~~

~~[Claim 116]~~

~~The method of treatment according to any one of claims 88 to 115, wherein the method is for treating at least one selected from the group consisting of breast cancer, gastric cancer, colorectal cancer, lung cancer, esophageal cancer, salivary gland cancer, gastroesophageal junction adenocarcinoma, biliary tract cancer, Paget's disease, pancreatic cancer, ovarian cancer, bladder cancer, prostate cancer, uterine carcinosarcoma, head and neck cancer, hepatocellular cancer, cervical cancer, brain tumor, glioma, eye tumor, thyroid cancer, thymus cancer, gallbladder cancer, lymphoma, leukemia, and myelodysplastic syndrome.~~